SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
technologies designed to provide physicians with clinically
actionable information to improve the outcomes of patients with
cancer, announces the availability of 10,000 nasopharyngeal
specimen collection kits for RT-PCR testing for SAR-CoV-2
(COVID-19) for physician ordering. Collected specimens will
be shipped overnight to Biocept's high-complexity, CLIA-certified,
CAP-accredited and BSL-2 safety level laboratory in San Diego with results returned to ordering
physicians in an estimated 24 to 48 hours.
"As previously reported, securing specimen collection kits to
conduct RT-PCR COVID-19 testing has been challenging both for
Biocept and other providers. We have solved our initial
supply chain challenge by obtaining the swabs, reagents and other
components of these kits, assembling them, and making them
available for physician ordering," said Michael Nall, Biocept's President and CEO.
"We continue to develop our own specimen collection media, which
will allow us to further control our supply chain. We expect
these Biocept-developed RT-PCR COVID-19 kits to be available in the
third quarter of 2020.
"We are pleased to be offering this testing during the
continuing pandemic, with RT-PCR testing providing the most
accurate results for detecting active COVID-19 virus," he
added. "As previously announced, we expanded our relationship
with Thermo Fisher Scientific to run these tests on their
FDA-approved for emergency-use authorization, or EUA, TaqPath™
molecular diagnostic platform. We believe we have a distinct
advantage in performing RT-PCR COVID-19 testing given our rapid
turnaround time, which is faster than many other labs."
Information for physician ordering of RT-PCR COVID-19 specimen
collection kits from Biocept is available on the company website at
www.biocept.com or by contacting customer service at 888-332-7729
or customerservice@biocept.com.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. Additionally,
Biocept is offering nationwide COVID-19 polymerase chain reaction
(PCR) testing to support public health efforts during this
unprecedented pandemic. For more information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding our development of our own specimen collection
media and that such development will allow us to control all
aspects of the supply chain, our expectation that Biocept-developed
RT-PCR COVID-19 kits will be available in the third quarter of
2020, the relative accuracy of RT-PCR testing, our ability to
perform RT-PCR COVID-19 testing faster than many other labs, the
ability of our platform to identify cancer mutations and
alterations, and the ability of our technologies to provide
physicians with clinically actionable information for treating and
monitoring patients diagnosed with cancer, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
You are cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. You are advised to review our
filings with the SEC, which can be accessed over the Internet at
the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-announces-the-availability-of-10-000-specimen-collection-kits-for-rt-pcr-covid-19-testing-301080854.html
SOURCE Biocept, Inc.